S3 E3: Brad Loncar on Whether Pricing Pressure is Coming in Oncology

Redeeming Value

Contenuto fornito da W2O Group. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da W2O Group o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

3y ago 24:33

MP3•Pagina principale dell'episodio

Serie archiviate ("Feed non attivo" status)

When? This feed was archived on May 30, 2023 00:27 (11M ago). Last successful fetch was on April 25, 2023 10:11 (1y ago)

Why? Feed non attivo status. I nostri server non sono riusciti a recuperare un feed valido per un periodo prolungato.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Launch prices in oncology have been rising -- a reflection, in part, of the growing clinical power of the medicines -- raising the question whether doctors, payers and others might try to push down prices of cancer medicines. Loncar Investment's Brad Loncar joins us to lend his perspective on the issue in a conversation that touches on the rise of Chinese biotech and the question of whether insurance companies are willing or able to intervene in the oncology market.

16 episodi

#Business News #Medicine #Access #Biotechnology #Drugpricing #Healthcare #Healtheconomics #Healthinsurance #Healthpolicy #Medical #Pbms #Pharmaceutical #Reimbursement #Value #Fitness #News #W2O Groups #Health and Well-Being